A comprehensive US analysis showed that progress in multiple myeloma survival has not been shared equally, with significant disparities persisting despite improved therapies.

Patients have been asking me about a recently published article that suggests a "'potential cure"' for myeloma is at hand. Here’s what I’ve been saying about it.

The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response ...

Multiple myeloma involves a comprehensive approach that combines blood tests, imaging, and bone marrow studies. Learn about ...

FALL RIVER, Mass. (WPRI) -- Multiple people have died after a fire broke out at an assisted living facility in Fall River Sunday night.

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who ...

A multiple myeloma diagnosis in 2017 significantly altered travel dynamics, necessitating adaptations like wheelchair-accessible transport. Despite health challenges, the spirit of adventure persists, ...

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or refractory multiple myeloma.

A new PET/CT imaging technique that visualizes activated fibroblasts in the heart muscle enables early detection of multiple forms of cardiomyopathy, according to research presented at the Society ...

Dr. Joshua K. Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Annual Meeting, highlighting what patients should ...